GlobeVerge
Home / business
MARKETS
AstraZeneca shares fall 8.9% over merger talks with US cancer drug firm
GlobeVerge has tracked this story since 11h ago.
Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale More than £17bn was wiped off the value of Britain’s biggest drugmaker, AstraZeneca, on Monday after a report that it was in discussions to take over its US rival Bristol My
Caution ahead70%
PositivePossible support for stability, investment or market confidence
RiskInflation, volatility, borrowing costs or weaker growth
More in Finance
- AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger
- 'The Odyssey' fuels Imax stock to all-time high. CEO calls momentum a 'flywheel'
- Government To Sell 6.5% Stake In LIC For Over Rs 30,000 Crore
- Raj Thackeray Claims Donation Theft At Mumbai's Siddhivinayak, Trust Reacts
GlobeVerge Signal: A transparent, keyword-based read on this story's tone and stakes—not financial, political or safety advice. The summary above is the original publisher's excerpt, not AI-generated or rewritten by GlobeVerge. Open the original source link before acting on any story.